Agonist News and Research

RSS

$GLP-1 therapy may help reduce fracture risk among adults with type 2 diabetes$

GLP-1 therapy may help reduce fracture risk among adults with type 2 diabetes

New research by UCLA Health found GLP-1 medications may reduce the risk of serious fractures for adults with type 2 diabetes.

4 Aug 2026

Food may taste different on GLP-1 drugs, but taste may not be the reason

The review suggests that patient-reported “taste changes” during GLP-1RA treatment may reflect reduced food enjoyment and motivation rather than consistent impairment of basic taste. The authors propose a sensory-liking-wanting framework while emphasizing that current human evidence remains heterogeneous and largely indirect.

4 Aug 2026

Ten-million-person study links semaglutide to lower COVID-19 mortality

Researchers analyzing claims from more than 10.1 million commercial insurance and Medicare Advantage enrollees found that semaglutide use was associated with a 49% lower adjusted hazard of COVID-19-related death. The observational findings corroborate earlier SELECT trial results but do not establish causation, making further prospective research essential.

30 Jul 2026

Europe risks missing target to eliminate viral hepatitis by 2030

While Europe has made steady progress in preventing hepatitis B and C, with the prevalence of hepatitis B now at near-zero levels among children below five years old, an uneven implementation of key measures means that the region is set to miss the 2030 target to eliminate viral hepatitis as a public health threat, according to new data from the European Centre for Disease Prevention and Control (ECDC) on World Hepatitis Day.

28 Jul 2026

A common dietary nutrient feeds a gut pathway linked to atrial fibrillation

Researchers linked higher plasma TMAO to prevalent atrial fibrillation in 5,090 people and found that TMAO or choline supplementation accelerated AF onset, progression, atrial remodeling, and electrical dysfunction in mice. Inhibiting gut microbial TMA production lowered circulating TMAO and delayed AF in mice, identifying a potential therapeutic pathway that now requires human testing.

27 Jul 2026

Cambridge scientists solve brain puzzle behind popular obesity drugs

Cambridge scientists have solved the mystery of why both stimulating and blocking a particular 'switch' in the brain can help people lose weight – findings which could help boost the effectiveness of obesity drugs.

24 Jul 2026

GLP-1 receptor agonists may increase hair loss risk

Use of glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity are associated with an increased risk of hair loss (alopecia) in adults with type 2 diabetes, finds a study published by The BMJ today.

22 Jul 2026

Generic semaglutide could improve diabetes treatment affordability in Canada

In a novel analysis examining the economic implications of generic semaglutide entering the Canadian market, researchers predict that the anticipated price reductions of up to 70% will dramatically increase both the cost-effectiveness and health system affordability of therapy options for patients with type 2 diabetes and high cardiorenal risk.

22 Jul 2026

Newer GLP-1 medications may reduce alcohol-related hospitalization risk

Use of newer GLP-1 receptor agonists (semaglutide or tirzepatide) for obesity or diabetes by people with alcohol-use disorder was associated with a reduction in alcohol-related admissions to hospital, finds a study published online in the open access journal BMJ Open.

21 Jul 2026

Semaglutide fuels rapid growth in US GLP-1RA use as payments rise

Nationally representative US data show GLP-1RA use rose 230% among adults with diabetes and 643% among those without reported diabetes between 2017 and 2022, largely driven by semaglutide. Mean annual out-of-pocket payments decreased, but mean total annual payments per user increased, raising concerns about long-term affordability.

20 Jul 2026

PET imaging reveals widespread brain receptor deficits in schizophrenia

A groundbreaking study using positron emission tomography (PET) imaging has found that patients with schizophrenia had significantly lower muscarinic acetylcholine M1 receptor availability (~13% to 19%) across multiple brain regions compared with healthy individuals.

16 Jul 2026

Nearly one in 10 Britons use or want weight-loss medication

The prevalence of GLP-1 receptor agonists for weight management in Great Britain highlights public interest and concerns over safety and prescribing practices.

13 Jul 2026

Study links GLP-1 treatment to fewer alcohol drinking days

Current GLP-1 receptor agonist prescriptions were associated with modestly lower AUDIT-C scores in a large, diverse US cohort. The difference appeared to reflect less frequent drinking rather than fewer drinks per occasion or fewer binge-drinking episodes.

13 Jul 2026

Semaglutide outperforms other GLP-1 drugs for weight loss in psychiatric populations

A network meta-analysis of nine randomized controlled trials found that once-weekly semaglutide showed the largest estimated weight-loss effect among GLP-1 receptor agonists tested in adults with mental illness and obesity or related metabolic risk. The authors cautioned that the findings remain preliminary because the evidence base was small, heterogeneous, and largely indirect.

9 Jul 2026

Stem cell study uncovers molecular pathway for enamel regeneration

Tooth enamel is the hardest substance in the human body, yet once damaged, it cannot regenerate naturally.

9 Jul 2026

Investigational drug ameliorates neuronal DNA damage and inflammation in Alzheimer's model

Accumulation of DNA damage in the brain's neurons may contribute to the development of Alzheimer's disease.

8 Jul 2026

Bio-Techne launches expanded R&D Systems AI-Engineered Designer Protein Portfolio

Bio-Techne Corporation, a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D Systems™ AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows.

From Bio-Techne 8 Jul 2026

New review shows why antidepressants often fail in Alzheimer’s and Parkinson’s depression

A Molecular Psychiatry review shows that depression in Alzheimer’s and Parkinson’s disease may reflect disease-specific molecular, neurotransmitter, inflammatory, and circuit-level disruptions rather than standard depression biology alone. It argues that broad antidepressants often show limited efficacy in these patients and that future trials should use biomarkers, neuroimaging, and symptom profiling to guide targeted treatments.

7 Jul 2026

U.S. obesity rates rose sharply between 1999 and 2023

Obesity rates among U.S. adults and children rose sharply in recent years and by 2023, 40% of adults and 20% of youth met the criteria for obesity, according to new, independent research published today in the American Heart Association's flagship journal Circulation.

7 Jul 2026

GLP-1 medications may improve long-term health for people with peripheral artery disease

GLP-1 receptor agonists (GLP-1 RA) medications were shown to reduce the number of deaths, amputations and hospitalizations among people with Type 2 diabetes who also had narrowed leg arteries associated with PAD (peripheral artery disease), according to new, independent research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association.

1 Jul 2026